Editorial: A historic settlement

In 1995, Purdue Pharma was granted permission by the Food and Drug Administration to market a new opioid called OxyContin. Within five years, the drug was generating a billion dollars annually. No wonder. The company funded research and paid doctors to overstate the benefits of the new drug while understating the risks. Sales representatives marketed OxyContin as a product “to start with and to stay with.”